SCHEMBL5220639

SCHEMBL5220639

Cn1cc(C=O)cc1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC10 Q969S8 2/20 0.49
HTT P42858 3/20 0.48
HDAC8 Q9BY41 2/20 0.45
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
CYP2C9 P11712 2/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
ATM Q13315 1/20 0.41
FNTA P49354 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9268443 0.84 HDAC10 (0.66) HDAC10HDAC8HDAC3HDAC4HDAC1
SCHEMBL5216779 0.79 HTT (0.43) HDAC10HTTHDAC8HDAC3HDAC4
SCHEMBL10944422 0.78 CYP2C9 (0.57) HDAC10HTTHDAC8HDAC3HDAC4
SCHEMBL6957822 0.75 HDAC10 (0.43) HDAC10HTTHDAC8HDAC3HDAC4
SCHEMBL6954324 0.75 GSK3B (0.54) HDAC10HTTHDAC8HDAC3HDAC4
SCHEMBL5216771 0.74 HTT (0.52) HDAC10HTTHDAC8HDAC3HDAC4
SCHEMBL1441399 0.73 HDAC8 (0.47) HDAC10HDAC8CYP2C9MEN1POLB
SCHEMBL3565290 0.73 HSD17B10 (0.70) CYP1A2HSD17B10MAPK1SRD5A2HPGD
Hydrochloric Acid SCHEMBL6955433 0.72 CYP2C9 (0.45) HDAC10HTTHDAC8HDAC3HDAC4
SCHEMBL11296235 0.72 HDAC10 (0.45) HDAC10HTTHDAC8KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458386-B1 AROYL PYRROLE HETEROERYL AND METHANOLS USEFUL FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER ORTHO MCNEIL PHARM INC (US) 2007-04-18 EP disclosed
US-20050148636-A1 Useful aroyl pyrrole heteroaryl methanones and methanols JANSSEN PHARMACEUTICA, N.V. (BE) 2005-07-07 US disclosed
US-6897319-B2 Useful aroyl pyrrole heteroaryl methanones and methanols ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-05-24 US disclosed
EP-1458386-A1 AROYL PYRROLE HETEROERYL AND METHANOLS USEFUL FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER Ortho-McNeil Pharmaceutical, Inc. (US) 2004-09-22 EP disclosed
US-20040058980-A1 Useful aroyl pyrrole heteroaryl methanones and methanols ORTHO-MCNEIL PHARMACEUTICALS, INC. 2004-03-25 US disclosed
US-20030181481-A1 Useful aroyl pyrrole heteroaryl methanones and methanols ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-09-25 US disclosed
WO-2003057219-A1 AROYL PYRROLE HETEROERYL AND METHANOLS USEFUL FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER ORTHO-MCNEIL PHARMACEUTICAL INC. (US) 2003-07-17 WO disclosed
WO-2003057147-A2 USEFUL AROYL PYRROLE HETEROARYL METHANONES AND METHANOLS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148636-A1 Useful aroyl pyrrole heteroaryl methanones and methanols CYP11B2, NLN, CNR2 HDAC10 1580/4885HTT 542/4885HDAC8 3935/4885
US-20040058980-A1 Useful aroyl pyrrole heteroaryl methanones and methanols CYP11B2, NLN, CNR2 HDAC10 1580/4885HTT 542/4885HDAC8 3935/4885
US-20030181481-A1 Useful aroyl pyrrole heteroaryl methanones and methanols CYP11B2, NLN, CNR2 HDAC10 1580/4885HTT 542/4885HDAC8 3935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.